Two studies suggest that T cells with stem-cell-like properties could work with antibody therapies to control HIV after a ...

Imunon Inc. (IMNN) reported its third-quarter 2025 financial results, highlighting a significant reduction in net loss and operating expenses. Despite these positive financial metrics, the company’s ...

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial ...

LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a ...

LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company ...

Good morning. My name is Darwin, and I will be your operator today. At this time, I would like to welcome you to IMUNON's Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] ...

Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 million in June, management is pushing ahead with plans to find partners ...

Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate, IMNN-001. Up Next: Wall Street trader’s 34-0 strategy goes public this ...

LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock ...

Imunon, Inc. (NASDAQ:IMNN), currently trading at $0.52 and with a market capitalization of $11 million, announced Monday that it has been granted an exception by a Nasdaq Hearing Panel to address its ...

LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral ...